Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2009
  • Online publication date: July 2016

Section 2: - Autoimmunity

References

Abdoul-Enein F, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003; 62(1): 25–33.
Abdoul-Enein F, et al. [Review] Mitochondrial damage and histotoxic hypoxia: A pathway of tissue injury in inflammatory brain disease? Acta Neuropathol (Berl) 2005; 109(1): 49–55.
Aktas O, et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005; 46(3): 421–32.
Albert M, et al. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Path Brain Pathol 2007; 17(2): 129–38.
Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979; 41(1): 81–91.
Ambrosini E, Aloisi F. Chemokines and glial cells: A complex network in the central nervous system. Neurochem Res 2004; 29: 1017–38.
Amiry-Moghaddam M, et al. An alpha-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc Natl Acad Sci USA 2003; 100(4): 2106–11.
Anthony DC, et al. Differential matrix metalloproteinase expression in cases of MS and stroke. Neuropath Appl Neurobiol 1997; 23: 406–15.
Babbe H, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192(3): 393–404.
Baig S, et al. Multiple sclerosis: Cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid. Scand J Immunol 1991; 33(1): 73–9.
Balashov KE, et al. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA 1999; 96(12): 6873–8.
Barnett MH, Prineas JW. Pathological Heterogeneity in Multiple Sclerosis: A Reflection of Lesion Stage? Ann Neurol 2004; 56(2): 309.
Bechtold DA, Smith KJ. Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci 2005; 233(1–2): 27–35. Review.
Berger T, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003; 349(2): 139–45.
Bezzi P, Volterra A. A neuron–glia signaling network in the active brain. Curr Opin Neurobiol 2001; 11(3): 387–94.
Bezzi P, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391(6664): 281–5.
Bjartmar CWJ, Trapp BD. Axonal loss in the pathology of MS: Consequences for understanding the progressive phase of the disease. J Neurol Sci 2003; 206(2): 165–71.
Bieber A, et al. Genetically dominant spinal cord repair in a murine model of chronic progressive multiple sclerosis. J Neuropathol Exp Neurol 2005; 64(1): 46–57.
Bitsch A, et al. Lesion development in Marburg’s type of acute multiple sclerosis: From inflammation to demyelination. Mult Scler 1999; 5: 138–46.
Bitsch A, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123 (Pt 6): 1174–83.
Bitsch A, et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol 2001; 49(6): 793–6.
Blakemore WF, et al. The presence of astrocytes in areas of demyelination influences remyelination following transplantation of oligodendrocyte progenitors. Exp Neurol 2003; 184(2): 955–63.
Bo L, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994; 36(5): 778–86.
Bo L, et al. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003a; 62(7): 723–32.
Bo L, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003b; 9(4): 323–31.
Bonetti B, Raine CS. Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997; 42(1): 74–84.
Booss J, et al. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 1983; 62(1–3): 219–32.
Bostock H, Sears T. The internodal axon membrane: Electrical excitability and continuous conduction in segmental demyelination. J Physiol (Lond) 1978; 280: 273–301.
Bourquin C, et al. Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis. Eur J Immunol 2000; 30(12): 3663–71.
Boven LA, et al. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 2006; 129(2): 517–26.
Brink BP, et al. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol 2005; 64(2): 147–55.
Broman T. Blood–brain barrier damage in multiple sclerosis supravital test-observations. Acta Neurol Scand 1964; 40: 21–4.
Brown GC. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Rad Biol Med 2002; 33(11): 1440–50.
Brown GC, et al. Interactions between nitric oxide, oxygen, reactive oxygen species and reactive nitrogen species. Biochem Soc Trans 2006; 34(5): 953–6.
Bruck W, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38(5): 788–96.
Bruck W, et al. Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42(5): 783–93.
Brueck W, et al. Oligodendrocytes in the early course of multiple sclerosis. Ann Neurol 1994; 35(1): 65–73.
Burgoon MP, Owens GP. B cells in multiple sclerosis. Front Biosci 2004; 9(3): 786–96.
Chang A, et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346(3): 165–73.
Christians ES, et al. Heat shock factor 1 and heat shock proteins: Critical partners in protection against acute cell injury. Crit Care Med 2002; 30(Suppl. 1): S43–50.
Coleman M. Axon degeneration mechanisms: Commonality amid diversity. Nat Rev Neurosci 2005; 6(11): 889–98.
Conde JR, Streit WJ. Microglia in the aging brain. J Neuropathol Exp Neurol 2006; 65(3): 199–203.
Confavreux C, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343(20): 1430–8.
Corcione A, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci USA 2004; 101: 11064–9.
Craner MJ, et al. Co-localization of sodium channel Nav1.6 and the sodium–calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 2004a; 127(2): 294–303.
Craner, MJ, et al. Molecular changes in neurons in multiple sclerosis: Altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci USA 2004b; 101(21): 8168–73.
Crocker SJ, et al. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am J Pathol 2006; 169: 2104–16.
Cross A, et al. B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001; 112: 1–14.
Cuzner M, et al. The expression of tissue-type plasminogen activator, matrix metalloproteinases and endogenous inhibitors in the central nervous system in multiple sclerosis: Comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55: 1194–204.
De Rosbo NK, Ben-Nun A. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. J Autoimmunol 1998; 11(4): 287–99.
Diemel LT, et al. Macrophages in CNS remyelination: Friend or foe? Neurochem Res 1998; 23(3): 341–7.
Dowling P, et al. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996; 184(4): 1513–8.
D’Souza S, et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184: 2361–70.
Dutta R, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478–89.
Egg R, et al. Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 2001; 7(5): 285–9.
Evangelou N, et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000; 47(3): 391–5.
Ferguson B, et al. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393–9.
Flavin MP, et al. Soluble macrophage factors trigger apoptosis in cultured hippocampal neurons. Neuroscience 1997; 80: 437–448.
Flavin MP, et al. Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Glia 2000; 29: 347–54.
Fogdell A, et al. Linkage analysis of HLA class II genes in Swedish multiplex families with multiple sclerosis. Neurology 1997; 48(3): 758–62.
Foote AK, Blakemore WF. Inflammation stimulates remyelination in areas of chronic demyelination. Brain 2005; 128(3): 528–39.
Forstermann U, et al. Nitric oxide synthase: Expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 1995; 352(4): 351–64.
Foster R, et al. Reorganization of the axon membrane in demyelinated peripheral nerve fibers: Morphological evidence. Science 1980; 210: 661–3.
Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 2002; 3(9): 705–14.
Friede RL, Bruck W. Macrophage functional properties during myelin degradation. Adv Neurol 1993; 59: 327–36.
Friese M, et al. Humanized mouse models for organ-specific autoimmune diseases. Curr Opin Immunol 2006; 18(6): 704–09.
Friese M, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005; 128(8): 1747–63.
Gay FW, et al. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997; 120: 1461–83.
Gaertner S, et al. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004; 63(12): 2381–3.
Geurts JJ, et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 2003; 126(8): 1755–66.
Giordana MT, et al. Abnormal ubiquitination of axons in normally myelinated white matter in multiple sclerosis brain. Neuropathol Appl Neurobiol 2002; 28(1): 35–41.
Giovannoni G, et al. The potential role of nitric oxide in multiple sclerosis. Mult Scler 1998; 4: 212–6.
Glabinski AR, Ransohoff RM. Chemokines and chemokine receptors in CNS pathology. J Neurovirol 1999a; 5(1): 3–12.
Glabinski AR, Ransohoff RM. Sentries at the gate: Chemokines and the blood–brain barrier. J Neurovirol 1999b; 5(6): 623–34.
Gold R, et al. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129(8): 1953–71.
Hafler DA, et al. Multiple sclerosis. Immunol Rev 2005; 204: 208–31.
Haase CG, et al. The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol 2001; 114(1–2): 220–5.
Hill KE, et al. Inducible nitric oxide synthase in chronic active multiple sclerosis plaques: Distribution, cellular expression and association with myelin damage. J Neuroimmunol 2004; 151(1–2): 171–9.
Hochmeister S, et al. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006; 65(9): 855–65.
Hoftberger R, et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol 2004; 14: 43–50.
Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci USA 2004; 101(Suppl 2): 14599–606.
Holley JE, et al. Astrocyte characterization in the multiple sclerosis glial scar. Neuropathol Appl Neurobiol 2003; 29(5): 434–44.
Hollsberg P, et al. Induction of anergy in CD8 T cells by B cell presentation of antigen. J Immunol 1996; 157(12): 5269–76.
Huseby ES, et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001; 194: 669–76.
Jung J, et al. Molecular characterization of an aquaporin cDNA from brain: Candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci USA 1994; 91: 13052–6.
Kabat EA, et al. Quantitative estimation of albumin and gamma globulin in normal and pathological cerebrospinal fluid by immunochemical methods. Am J Med 1948; 4: 653–62.
Karni A, et al. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol 1999; 56(3): 311–5.
Keegan M, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366(9485): 579–82.
Kerlero De Rosbo N, et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: Reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol 1997; 27(11): 3059–69.
Kermode AG, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis. An MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40: 229.
Kerschensteiner M, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of inflammation? J Exp Med 1999; 189(5): 865–70.
Kidd D, et al. Cortical lesions in multiple sclerosis. Brain 1999; 122(Pt 1): 17–26.
Kivisakk P, et al. High numbers of perforin mRNA expressing CSF cells in MS with gadolinium-enhancing brain MRI lesions. Acta Neurol Scand 1999; 100(1): 18–24.
Kornek B, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157(1): 267–76.
Kotter MR, et al. Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 2001; 35(3): 204–12.
Kuhlmann T et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125(10): 2202–12.
Kutzelnigg A, Lassmann H. Cortical demyelination in multiple sclerosis: A substrate for cognitive deficits? J Neurol Sci 2006; 245(1–2): 123–6.
Kutzelnigg A, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128(11): 2705–12.
Kwon EE, Prineas JW. Blood–brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 1994; 53(6): 625–36.
Lalive PH, Genain CP. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103(7): 2280–5.
Lampasona V, et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004; 62: 2092–4.
Lassmann H, et al. Experimental allergic encephalomyelitis: The balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions. Acta Neuropathol (Berl) 1988; 75(6): 566–76.
Lassmann H. Axonal injury in multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74: 695–7.
Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: A critical re-appraisal. Trends Immunol 2004; 25(3): 132–7.
Lassman H. Multiple sclerosis pathology: Evolution of pathogenetic concepts. Brain Pathol 2005; 15(3): 217–22.
Lennon V, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364(9451): 2106–12.
Lennon V, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202(4): 473–7.
Lim ET, et al. Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Mult Scler 2005; 11(4): 492–4.
Linberg RL, et al. The expression profile of matrix metalloproteinases and their inhibitors in lesions and normal appearing white matter of multiple sclerosis. Brain 2001; 124: 1743–53.
Lindert RB, et al. Multiple sclerosis: B- and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999; 122 (Pt 11): 2089–100.
Linington C, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130(3): 443–54.
Linker RA, et al. CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002; 8: 620–4.
Liu J, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158: 2057–66.
Lovas G, et al. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000; 123(2): 308–17.
Lu W, et al. Involvment of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J Neurosci 2002; 22: 10781–9.
Lucchinetti C, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999; 122 (12): 2279–95.
Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707–17.
Lucchinetti CF, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125(7): 1450–61.
Lucchinetti CF, et al. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004; 56(2): 308.
Lucchinetti CF, et al. The pathology of multiple sclerosis. Neurol Clin 2005; 23(1): 77–105, vi.
Ludwin S, et al. Evidence of a “dying back” gliopathy in demyelinating disease. Ann Neurol 1981; 9: 301–05.
Luster AD. Chemokines – chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338(7): 436–45.
Mahad DJ, et al. Expression of chemokine receptors CCR1 and CCR5 reflects differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions. J Neuropathol Exp Neurol 2004; 63(3): 262–73.
Mahad D, et al. Modulating CCR2 and CCL2 at the blood–brain barrier: Relevance for multiple sclerosis pathogenesis. Brain 2006; 129(Pt 1): 212–23.
Mandler RN, et al. Devic’s neuromyelitis optica: A clinicopathological study of 8 patients. Ann Neurol 1993; 34(2): 162–8.
Mantegazza R, et al. Anti-MOG autoantibodies in Italian multiple sclerosis patients: Specificity, sensitivity and clinical association. Int Immunol 2004; 16(4): 559–65.
Mantovani A, et al. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549–55.
Mantovani A, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25(12): 677–86.
Mantovani A, et al. Macrophage polarization comes of age. Immunity 2005; 23(4): 344–6.
Marta CB, et al. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc Natl Acad Sci USA 2005a; 102(39): 13992–7.
Marta CB, et al. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis. J Biol Chem 2005b; 280(10): 8985–93.
Martino G, et al. Cells producing antibodies specific for myelin basic protein region 70–89 are predominant in cerebrospinal fluid from patients with multiple sclerosis. Eur J Immunol 1991; 12: 2971–6.
Martino G, et al; Cytokines and immunity in multiple sclerosis: The dual signal hypothesis. J Neuroimmunol 2000; 109(1): 3–9.
Matute C, et al. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001; 24(4): 224–30.
Medana I, et al. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001; 159(3): 809–15.
Merkler D, et al. Differential macrophage/microglia activation in neocortical EAE lesions in the marmoset monkey. Brain Pathol 2006; 16(2): 117–23.
Mew I, et al. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998; 4(2): 55–62.
Moalem G, et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5(1): 49–55.
Moalem G, et al. Production of neurotrophins by activated T cells: Implications for neuroprotective autoimmunity. J Autoimmun 2000; 15(3): 331–45.
Nedergaard M, et al. Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci 2002; 3(9): 748–55.
Neumann H, et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25(6): 313–9.
Nitsch R, et al. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. J Neurosci 2004; 24(10): 2458–64.
Olsson T, et al. Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol 1990; 27(2): 132–6.
O’Connor KC, et al. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol 2005; 175(3): 1974–82.
Oleszak EL, et al. Inducible nitric oxide synthase and nitrotyrosine are found in monocytes/macrophages and/or astrocytes in acute, but not in chronic multiple sclerosis. Clin Diagn Lab Immunol 1998; 5: 438–45.
Ota K, et al. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990; 346(6280): 183–7.
Ozawa K, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994; 117: 1311–22.
Panitch HS, et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987a; 1: 893–5.
Panitch HS, et al. Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 1987b; 37: 1097–102.
Patrikios P et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129(12): 3165–72.
Peter H, et al. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003; 23(35): 11127–35.
Peterson JW, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50(3): 389–400.
Peterson JW, rapp BD. Neuropathobiology of multiple sclerosis. Neurol Clin 2005; 23(1): 107–29.
Pette M, et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 1990; 40(11): 1770–6.
Piddlesden S, et al. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993; 143(2): 555–64.
Pitt D, et al. Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003; 61(8): 1113–20.
Pittock SJ, et al. Clinical course, pathological correlations, and outcome of biopsy proved inflammatory demyelinating disease. J Neurol Neurosurg Psychiatry 2005; 76(12): 1693–7.
Plumb J, et al. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002; 12(2): 154–69.
Pomeroy I, et al. Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis. Brain 2005; 128(11): 2713–21.
Prineas JW, et al. Multiple sclerosis. Pathology of recurrent lesions. Brain 1993; 116(3): 681–93.
Prineas JW, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50(5): 646–5.
Proescholdt MA, et al. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 2002; 61: 914–25.
Raff M, et al. Axonal self-destruction and neurodegeneration. Science 2002; 296(5569): 868–71.
Ransohoff RM, et al. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3(7): 569–81.
Redford EJ, et al. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997; 120(12): 2149–57.
Reindl M, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999; 122(11): 2047–56.
Rodriguez M. Virus-induced demyelination in mice: “Dying back” of oligodendrocytes. Mayo Clin Proc 1985; 60: 433–8.
Rodriguez M, Scheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct Pathol 1994; 18(1–2): 3–13.
Roemer S, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130(5): 1194–205.
Rostagno A, et al. Complement activation in chromosome 13 dementias. Similarities with Alzheimer’s disease. J Biol Chem 2002; 277(51): 49782–90.
Rovaris M, et al. Correlation between MRI and short-term clinical activity in multiple sclerosis: Comparison between standard- and triple-dose Gd-enhanced MRI. Eur Neurol 1999; 41(3): 123–7.
Rovaris M, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5(4): 343–54.
Sadatipour BT, et al. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol 1998; 44: 980–3.
Saoudi A, et al. Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: Evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells. J Exp Med 1995; 182(2): 335–44.
Schwab C, McGeer PL. Complement activated C4d immunoreactive oligodendrocytes delineate small cortical plaques in multiple sclerosis. Exp Neurol 2002; 174(1): 81–8.
Schwartz M, et al. Microglial phenotype: Is the commitment reversible? Trends Neurosci 2006; 29(2): 68–74.
Simpson J, et al. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol 2000; 108 (1–2): 192–200.
Serafini B, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14(2): 164–74.
Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004; 5(6): 437–48.
Skou JC. Nobel Lecture. The identification of the sodium pump. Biosci Rep 1998; 18(4): 155–69.
Skulina C, et al. Multiple sclerosis: Brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 2004; 101 (8): 2428–33.
Smith KJ, et al. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49(4): 470–6.
Smith KJ, et al. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1(4): 232–41.
Sorensen TL, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103(6): 807–15.
Stadelmann C, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells? Brain 2002; 125(1): 75–85.
Stadelmann C, et al. Tissue preconditioning may explain concentric lesions in Balo’s type of multiple sclerosis. Brain 2005; 128(5): 979–87.
Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85(3): 299–302.
Storch MK, et al. Multiple sclerosis: In situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998a; 43(4): 465–71.
Storch MK, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998b; 8(4): 681–94.
Streit W. Microglial senescence: Does the brain’s immune system have an expiration date? Trends Neurosci 2006; 29(9): 506–10.
Stys PK, et al. Axonal degeneration in multiple sclerosis: Is it time for neuroprotective strategies? Ann Neurol 2004; 55(5): 601–3.
Sun J, et al. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991; 146(5): 1490–5.
Tavolato BF. Immunoglobulin G distribution in multiple sclerosis brain. An immunofluorescence study. Neurol Sci 1975; 24(1): 1–11.
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study, 1998.
Trapp BD, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338(5): 278–85.
Trebst C, et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001; 159(5): 1701–10.
Trebst C, et al. Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). Neuropathol Appl Neurobiol 2003; 29(6): 584–95.
Urich E, et al. Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors. Proc Natl Acad Sci USA 2006; 103(49): 18697–702.
Van Horssen J, et al. Matrix metalloproteinase-19 is highly expressed in active multiple sclerosis lesions. Neuropathol Appl Neurobiol 2006; 32(6): 585–93.
van Walderveen MA, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282–8.
Vass K, et al. Localization of 70-kDa stress protein induction in gerbil brain after ischemia. Acta Neuropathol (Berl) 1988; 77(2): 128–35.
Vercellino M, et al. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol 2005; 64(12): 1101–7.
Vos CM, et al. Matrix metalloproteinase-12 is expressed in phagocytotic macrophages in active multiple sclerosis lesions. J Neuroimmunol 2003; 138(1–2): 106–14.
Warrington AE, et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA 2000; 97(12): 6820–5.
Washington R, et al. Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 1994; 35: 89–97.
Waxman SG. Ions, energy and axonal injury: Towards a molecular neurology of multiple sclerosis. Trends Mol Med 2006a; 12(5): 192–5.
Waxman SG. Axonal conduction and injury in multiple sclerosis: The role of sodium channels. Nat Rev Neurosci 2006b; 7(12): 932–41.
Wegner C, et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67(6): 960–7.
Werner P, et al. Multiple sclerosis: Altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50(2): 169–80.
Wolswijk G, et al. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neuroscience 1998; 18(2): 601–9.
Xiao BG, et al. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol 1991; 31(2): 91–6.
Yamashita T, et al. Changes in nitrite and nitrate (NO2/NO3) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 1997; 153(1): 32–4.
Yasojima K, et al. Up-regulated production and activation of the complement system in Alzheimer’s disease brain. Am J Pathol 1999; 154(3): 927–36.
Yednock TA, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356(6364): 63–6.
Zhou D, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103(50): 19057–62.

References

Aharoni R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003; 100(24): 14157.
Aharoni R, et al. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 2005; 102(52): 19045.
Airaksinen MS, Saarma M. The GDNF family: Signaling, biological functions and therapeutic value. Nat Rev Neurosci 2002; 3(5): 383.
Bareyre FM, et al. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat. Neurosci 2004; 7(3): 269.
Bazan JF, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385(6617): 640.
Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 2004; 55(5): 607.
Besser M, Wank R. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 1999; 162(11): 6303.
Bitsch A, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123(6): 1174.
Bjartmar C, Trapp BD. Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences. Curr Opin Neurol 2001; 14(3): 271.
Bjartmar C, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000; 48(6): 893.
Black JA, et al. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 2006; 129(12): 3196.
Braun A, et al. Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 1999; 21(4): 537.
Burns J, Rosenzweig A, Zweiman B, Lisak RP. Isolation of myelin-basic protein-reactive T cell lines from normal human blood. Cell Immunol 1983; 81(2): 435–440.
Cardona AE, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9(7): 917.
Confavreux C, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343(20): 1430.
De Stefano N, et al. Axonal damage correlates with disability in patients with relapsing–remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121(8): 1469.
Ehrhard PB, et al. Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. Proc Natl Acad Sci USA 1993; 90(23): 10984.
Farina C, et al. Glatiramer acetate in multiple sclerosis: Update on potential mechanisms of action. Lancet Neurol 2005; 4(9): 567.
Flugel A, et al. Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: Inhibition of monocyte transendothelial migration. Eur J Immunol 2001; 31(1): 11.
Hammarberg H, et al. Neuroprotection by encephalomyelitis: Rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000; 20(14): 5283.
Harrison JK, et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglial. Proc Natl Acad Sci USA 1998; 95(18): 10896.
Hauben E, et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci 2000; 20(17): 6421.
Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: Genes, inflammation, and neurodegeneration. Neuron 2006; 52(1): 61.
Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997; 120(5): 865.
Huang D, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006; 20(7): 896.
Hulshof S, et al. CX3CL1 and CX3CR1 expression in human brain tissue: Noninflammatory control versus multiple sclerosis. J Neuropathol Exp Neurol 2003; 62(9): 899.
Imai T, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91(4): 521.
Jones TB, et al. Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: Implications for autoimmune vaccine therapy. J Neurosci 2002; 22(7): 2690.
Jones TB, et al. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J Neurosci 2004; 24(15): 3752.
Kalled SL. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006; 18(5): 290.
Kapoor R. Neuroprotection in multiple sclerosis: Therapeutic strategies and clinical trial design. Curr Opin Neurol 2006; 19(3): 255.
Kapoor R, et al. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 2003; 53(2): 174.
Kerschensteiner M, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: A neuroprotective role of inflammation? J Exp Med 1999; 189(5): 865.
Kerschensteiner M, et al. Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. Ann Neurol 2003; 53(3): 292.
Kerschensteiner M, et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med 2004; 200(8): 1027.
Killestein J, Polman CH. Current trials in multiple sclerosis: Established evidence and future hopes. Curr Opin Neurol 2005; 18(3): 253.
Knoblach SM et al. Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. J Neuroimmunol 1999; 95(1–2): 115.
Kornek B, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157(1): 267.
Kramer R, et al. Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med 1995; 1(11): 1162.
Krumbholz M, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201(2): 195.
Kutzelnigg A, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128(11): 2705.
Lewin GR, Barde YA. Physiology of the neurotrophins.Annu Rev Neurosci 1996; 19: 289.
Liu L, et al. S100B-induced microglial and neuronal IL-1 expression is mediated by cell type-specific transcription factors. J Neurochem 2005; 92(3): 546.
Losseff NA, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996; 119(6): 2009.
Lu B, Acute and long-term synaptic modulation by neurotrophins. Prog Brain Res 2004; 146: 137.
Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci 2005; 6(8): 603.
Medana I, et al. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001; 159(3): 809.
Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation.Ann Neurol 2006; 59(6): 880.
Moalem G, et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5(1): 49.
Moalem G, et al. Production of neurotrophins by activated T cells: Implications for neuroprotective autoimmunity. J Autoimmun 2000; 15(3): 331.
Neumann H. Microglia: A cellular vehicle for CNS gene therapy. J Clin Invest 2006; 116(11): 2857.
Neumann H, et al. Interferon gamma gene expression in sensory neurons: Evidence for autocrine gene regulation. J Exp Med 1997; 186(12): 2023.
Neumann H, et al. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: Involvement of the p75 neurotrophin receptor. Proc Natl Acad Sci U SA 1998; 95(10): 5779.
Newman TA, et al. T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 2001; 124(11): 2203.
Pette M, et al. Myelin autoreactivity in multiple sclerosis: Recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990; 87(20): 7968.
Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354(9): 899.
Rapalino O, et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998; 4(7): 814.
Serpe CJ, et al. Exacerbation of facial motoneuron loss after facial nerve transection in severe combined immunodeficient (scid) mice. J Neurosci 1999; 19(11): RC7.
Smith KJ, et al. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49(4): 470.
Soriano SG, et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia–reperfusion injury. J Neuroimmunol 2002; 125(1–2): 59.
Stadelmann C, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: Neuroprotective interactions between immune and neuronal cells? Brain 2002; 125(1): 75.
Storch MK, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8(4): 681.
Sunnemark D, et al. CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. J Neuroinflamm 2005; 2: 17.
Thoenen H, Sendtner M. Neurotrophins: From enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat Neurosci 2002; 5(Suppl): 1046.
Tomac A, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995; 373(6512): 335.
Tomac AC, et al. Effects of cerebral ischemia in mice deficient in Persephin. Proc Natl Acad Sci USA 2002; 99(14): 9521.
Torcia M, et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 1996; 85(3): 345.
Trapp BD, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338(5): 278.
van Waesberghe JH, et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46(5): 747.
Vargas-Leal V, et al. Expression and function of glial cell line-derived neurotrophic factor family ligands and their receptors on human immune cells. J Immunol 2005; 175(4): 2301.
Villoslada P, et al. Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 2000; 191(10): 1799.
Wang LJ, et al. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci 2002; 22(16): 6920.
Waxman SG. Nitric oxide and the axonal death cascade. Ann Neurol 2003; 53(2): 150.
Yoles E, et al. Protective autoimmunity is a physiological response to CNS trauma. J Neurosci 2001; 21(11): 3740.
Ziemssen T, et al. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: Implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 2002; 125(11): 2381.
Ziv Y, et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 2006; 9(2): 268.

References

Albert ML, Darnell RB. Paraneoplastic neurological degenerations: keys to tumour immunity. Nat Rev Cancer 2004; 4(1): 36–44.
Albert ML, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4(11): 1321–4.
Albert ML, et al. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000; 47: 9–17.
Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6(3): 205–17.
Al-Sabbagh A, et al. Antigen-driven tissue-specific suppression following oral tolerance: Orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 1994; 24(9): 2104–9.
Babbe H, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000; 192(3): 393–404.
Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 2004; 55(4): 458–68.
Bennett SR, et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997; 186(1): 65–70.
Bergmann CC, et al. Microglia exhibit clonal variability in eliciting cytotoxic T lymphocyte responses independent of class I expression. Cell Immunol 1999; 198(1): 44–53.
Bitsch A, et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000; 123(6): 1174–83.
Booss J, et al. Immunohistological analysis of T lymphocyte subsets in the central nervous system in chronic progressive multiple sclerosis. J Neurol Sci 1983; 62(1–3): 219–32.
Bugawan TL, et al. High-resolution HLA class I typing in the CEPH families: Analysis of linkage disequilibrium among HLA loci. Tissue Antigens 2000; 56(5): 392–404.
Calzascia T, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005; 22(2): 175–84.
Carson MJ, et al. Disproportionate recruitment of CD8+ T cells into the central nervous system by professional antigen-presenting cells. Am J Pathol 1999; 154(2): 481–94.
Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 1996; 93(10): 4529–36.
De Vos AF, et al. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol 2002; 169(10): 5415–23.
Dressel A, et al. Autoantigen recognition by human CD8 T cell clones: Enhanced agonist response induced by altered peptide ligands. J Immunol 1997; 159(10): 4943–51.
Ebers GC, et al. A full genome search in multiple sclerosis. Nat Genet 1996; 13(4): 472–6.
Engelhorn ME, et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006; 12(2): 198–206.
Fabry Z, et al. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS. Immunol Today 1994; 15(5): 218–24.
Furneaux HF, et al. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990; 40(7): 1085–91.
Gay FW, et al. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997; 120(8): 1461–83.
Gordon LB, et al. Normal cerebrospinal fluid suppresses the in vitro development of cytotoxic T cells: Role of the brain microenvironment in CNS immune regulation. J Neuroimmunol 1998; 88(1–2): 77–84.
Greter M, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005; 11(3): 328–34.
Hatterer E, et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 2006; 107(2): 806–12.
Hawkins BT, Davis TP. The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57(2): 173–85.
Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19: 47–64.
Heath WR, et al. Cross-tolerance: A pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998; 187(10): 1549–53.
Hickey WF. Migration of hematogenous cells through the blood–brain barrier and the initiation of CNS inflammation. Brain Pathol 1991; 1(2): 97–105.
Hickey WF. Leukocyte traffic in the central nervous system: The participants and their roles. Semin Immunol 1999; 11(2): 125–37.
Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 1988; 239(4837): 290–2.
Hickey WF, et al. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28(2): 254–60.
Huseby ES, et al. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001; 194(5): 669–76.
Karman J, et al. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 2004; 173(4): 2353–61.
Kort JJ, et al. Efficient presentation of myelin oligodendrocyte glycoprotein peptides but not protein by astrocytes from HLA-DR2 and HLA-DR4 transgenic mice. J Neuroimmunol 2006; 173(1–2): 23–34.
Kurts C, et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med 1996; 184(3): 923–30.
Kurts C, et al. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med 1997; 186(12): 2057–62.
Kurts C, et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci USA 1999; 96(22): 12703–7.
Lang A, Nikolich-Zugich J. Development and migration of protective CD8+ T cells into the nervous system following ocular herpes simplex virus-1 infection. J Immunol 2005; 174(5): 2919–25.
Lanzavecchia A. Immunology. Licence to kill [news; comment]. Nature 1998; 393(6684): 413–14.
Lauterbach H, et al. Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infection. J Exp Med 2006; 203(8): 1963–75.
Lawson LJ, et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990; 39(1): 151–70.
Lee JW, et al. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat Immunol 2007; 8(2): 181–90.
Lindsey JW, et al. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 1994; 36(2): 183–9.
Lucchinetti C, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707–17.
McMahon EJ, et al. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005; 11(3): 335–9.
McRae BL, et al. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 1995; 182(1): 75–85.
Miller SD, et al. Blockade of CD28/B7–1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995; 3(6): 739–45.
Neumann H. Control of glial immune function by neurons. Glia 2001; 36(2): 191–9.
Neumann H, et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 2002; 25(6): 313–19.
Oksenberg JR, et al. Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients. Nature 1990; 345(6273): 344–6.
Pashenkov M, Link H. Dendritic cells and immune responses in the central nervous system. Trends Immunol 2002; 23(2): 69–70.
Ransohoff RM, et al. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3(7): 569–81.
Reese TS, Karnovsky MJ. Fine structural localization of a blood–brain barrier to exogenous peroxidase. J Cell Biol 1967; 34(1): 207–17.
Reichmann G, et al. Dendritic cells and dendritic-like microglia in focal cortical ischemia of the mouse brain. J Neuroimmunol 2002; 129(1–2): 125–32.
Rousseau A, et al. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 2005; 71(3): 231–6.
Santambrogio L, et al. Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA 2001; 98(11): 6295–300.
Sawcer S, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996; 13(4): 464–8.
Seamons A, et al. Endogenous myelin basic protein is presented in the periphery by both dendritic cells and resting B cells with different functional consequences. J Immunol 2006; 177(4): 2097–106.
Serafini B, et al. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 2000; 157(6): 1991–2002.
Serot JM, et al. Monocyte-derived IL-10-secreting dendritic cells in choroid plexus epithelium. J Neuroimmunol 2000; 105(2): 115–9.
Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996; 85(3): 299–302.
Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 1999; 24(3): 511–4.
Steinman RM, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000; 191(3): 411–6.
Suter T, et al. The brain as an immune privileged site: Dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol 2003; 33(11): 2998–3006.
Tsuchida T, et al. Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. Proc Natl Acad Sci USA 1994; 91(23): 10859–63.
Tsukada N, et al. Adhesion of cerebral endothelial cells to lymphocytes from patients with multiple sclerosis. Autoimmunity 1993; 14(4): 329–33.
Tuohy VK, et al. Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 1997; 99(7): 1682–90.
Tuohy VK, et al. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 1999; 189(7): 1033–42.
Van Oosten BW, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997; 49(2): 351–7.
Vass K, Lassmann H. Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system. Am J Pathol 1990; 137(4): 789–800.
Voltz R, et al. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1998; 51(4): 1146–50.
Walter BA, et al. The olfactory route for cerebrospinal fluid drainage into the peripheral lymphatic system. Neuropathol Appl Neurobiol 2006b; 32(4): 388–96.
Walter L, Albert ML. Cross-presented intracranial antigen primes CD8+ T cells. J Immunol 2007; 178(10): 6038–42.
Walter U, Santamaria P. CD8+ T cells in autoimmunity. Curr Opin Immunol 2005; 17(6): 624–31.
Yamada S, et al. Albumin outflow into deep cervical lymph from different regions of rabbit brain. Am J Physiol 1991; 261(4 Pt 2): H1197–204.
Yu M, et al. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease. J Exp Med 1996; 183(4): 1777–88.

References

Alemdar M, et al. The importance of EEG and variability of MRI findings in acute hemorrhagic leukoencephalitis. Eur J Neurol 2006; 13(11): e1–3.
Amit R, et al. Acute, severe, central and peripheral nervous system combined demyelination. Pediatr Neurol 1986; 2(1): 47–50.
Apak RA, et al. Acute disseminated encephalomyelitis in childhood: Report of 10 cases. J Child Neurol 1999; 14(3): 198–201.
Aydin A, et al. Acute disseminated encephalomyelitis presenting with bilateral transient amaurosis. Pediatr Neurol 2005; 32(1): 60–3.
Baum PA, et al. Deep gray matter involvement in children with acute disseminated encephalomyelitis. Am J Neuroradiol 1994; 15(7): 1275–83.
Boe J, et al. Corticosteroid treatment for acute meningoencephalitis: A retrospective study of 346 cases. Br Med J 1965; 5442: 1094–5.
Brass SD, et al. Multiple sclerosis vs acute disseminated encephalomyelitis in childhood. Ped Neurol 2003; 29(3): 227–31.
Brenner D, et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. Am J Roentgenol 2001; 176(2): 289–96.
Caldemeyer KS, et al. MRI in acute disseminated encephalomyelitis. Neuroradiology 1994; 36(3): 216–20.
Dale RC, Branson JA. Acute disseminated encephalomyelitis or multiple sclerosis: Can the initial presentation help in establishing a correct diagnosis? Arch Dis Childhood 2005; 90(6): 636–9.
Dale RC, et al. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000; 123(Pt 12): 2407–22.
Dale RC, et al. Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol 2001; 50(5): 588–95.
de Campo JF, et al. Is informed consent necessary for paediatric computed tomography? J Paed Child Hlth 2003; 39(6): 399–400.
Epperson LW, et al. Cranial MRI in acute disseminated encephalomyelitis. Neurology 1988; 38(2):332–3.
Gupte G, et al. Acute disseminated encephalomyelitis: A review of 18 cases in childhood. J Paed Child Hlth 2003; 39(5): 336–342.
Hahn CD, et al. Neurocognitive outcome after acute disseminated encephalomyelitis. Ped Neurol 2003; 29(2): 117–23.
Hartung HP, Grossman RI. ADEM: Distinct disease or part of the MS spectrum? Neurology 2001; 56(10): 1257–60. [Erratum appears in Neurology 2001; 57(6): 1146.]
Hartung HP, et al. Circulating adhesion molecules and inflammatory mediators in demyelination: A review. Neurology 1995; 45(6 Suppl. 6): S22–32.
Hawley RJ. Early high-dose methylprednisolone in acute disseminated encephalomyelitis. Neurology 1998; 51(2): 644–5.
Heick A, Skriver E. Chlamydia pneumoniae-associated ADEM. Eur J Neurol 2000; 7(4): 435–8.
Hofer M, et al. Acute hemorrhagic leukoencephalitis (Hurst’s disease) linked to Epstein–Barr virus infection. Acta Neuropathol 2005; 109(2): 226–30.
Hurst E. Acute haemorrhagic leucoencephalitis: A previously unidentified entity. Med J Aust 1941; 1: 1–6.
Hynson JL, et al. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001; 56(10): 1308–12.
Jacobs RK, et al. Neuropsychological outcome after acute disseminated encephalomyelitis: Impact of age at illness onset. Ped Neurol 2004; 31(3): 191–7.
Kaji M, et al. Survey of herpes simplex virus infections of the central nervous system, including acute disseminated encephalomyelitis, in the Kyushu and Okinawa regions of Japan. Mult Scler 1996; 2(2): 83–7.
Kamei A, et al. Acute disseminated demyelination due to primary human herpesvirus-6 infection. Eur J Pediatr 1997; 156(9): 709–12.
Kanter DS, et al. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology 1995; 45(4): 824–7.
Karelitz S, Eisenberg M. Measles encephalitis. Evaluation of treatment with adrenocorticotropin and adrenal corticosteroids. Pediatrics 1961; 27: 811–18.
Keegan M, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58(1): 143–6.
Kepes JJ. Large focal tumor-like demyelinating lesions of the brain: Intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol 1993; 33(1): 18–27.
Kesselring J, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990; 113(Pt 2): 291–302.
Khong P-L, et al. Childhood acute disseminated encephalomyelitis: The role of brain and spinal cord MRI. Ped Radiol 2002; 32(1): 59–66.
Khurana DS, et al. Acute disseminated encephalomyelitis in children: Discordant neurologic and neuro-imaging abnormalities and response to plasmapheresis. Pediatrics 2005; 116(2): 431–6.
Kimura S, et al. Serial magnetic resonance imaging in children with postinfectious encephalitis. Brain Dev 1996; 18(6): 461–5.
Kinoshita A, et al. Inflammatory demyelinating polyradiculitis in a patient with acute disseminated encephalomyelitis (ADEM). J Neurol Neurosurg Psychiatry 1996; 60(1): 87–90.
Kleiman M, Brunquell P. Acute disseminated encephalomyelitis: Response to intravenous immunoglobulin. J Child Neurol 1995; 10(6): 481–3.
Krupp LB, et al. Consensus definitions proposed for pediatric multiple sclerosis and related childhood disorders. Neurology 2007; 68(16 Suppl. 2): S7–12.
Kuperan S, et al. Acute hemorrhagic leukoencephalitis vs ADEM: FLAIR MRI and neuropathology findings. Neurology 2003; 60(4): 721–2.
Leake JA, et al. Acute disseminated encephalomyelitis in childhood: Epidemiologic, clinical and laboratory features. Pediatr Infect Dis J 2004; 23(8): 756–64.
Leake JAD, et al. Pediatric acute hemorrhagic leukoencephalitis: Report of a surviving patient and review. Clin Infect Dis 2002; 34(5): 699–703.
Lee HY, et al. Serial MR imaging findings of acute hemorrhagic leukoencephalitis: A case report. Am J Neuroradiol 2005; 26(8): 1996–9.
Lee SJ, Benveniste EN. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 1999; 98(2): 77–88.
Mader I, et al. Acute haemorrhagic encephalomyelitis (AHEM): MRI findings. Neuropediatrics 2004; 35(2): 143–6.
Martens-Le Bouar H, Korinthenberg R. Polyradiculoneuritis with myelitis: A rare differential diagnosis of Guillain–Barre syndrome. Neuropediatrics 2002; 33(2): 93–6.
Martino D, et al. Soluble adhesion molecules in acute disseminated encephalomyelitis. Pediatr Neurol 2005; 33(4): 255–8.
Menge T, et al. Acute disseminated encephalomyelitis: An update. Arch Neurol 2005; 62(11): 1673–80.
Mikaeloff Y, et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004a; 127(Pt 9): 1942–7.
Mikaeloff Y, et al. First episode of acute CNS inflammatory demyelination in childhood: Prognostic factors for multiple sclerosis and disability. J Pediat 2004b; 144(2): 246–52.
Miller DH, et al. Acute disseminated encephalomyelitis presenting as a solitary brainstem mass. J Neurol Neurosurg Psychiatry 1993; 56(8): 920–2.
Murray BJ, et al. Severe acute disseminated encephalomyelitis with normal MRI at presentation. Neurology 2000; 55(8): 1237–8.
Murthy SNK, et al. Acute disseminated encephalomyelitis in children. Pediatrics 2002; 110(2 Pt 1): e21.
Nasr JT, et al. ADEM: literature review and case report of acute psychosis presentation. Pediatr Neurol 2000; 22(1): 8–18.
O’Riordan JI, et al. Long term MRI follow-up of patients with post infectious encephalomyelitis: Evidence for a monophasic disease. J Neurol Sci 1999; 167(2): 132–6.
Ohtaki E, et al. Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination. Ped Neurol 1992; 8(2): 137–9.
Ozawa H, et al. Acute disseminated encephalomyelitis associated with poliomyelitis vaccine. Ped Neurol 2000; 23(2): 177–9.
Pasternak JF, et al. Steroid-responsive encephalomyelitis in childhood. Neurology 1980; 30(5): 481–6.
Perniola T, et al. A case of Landau-Kleffner syndrome secondary to inflammatory demyelinating disease. Epilepsia 1993; 34(3): 551–6.
Pohl D, et al. CSF characteristics in early-onset multiple sclerosis. Neurology 2004; 63(10): 1966–7.
Pohl-Koppe A, et al. Myelin basic protein reactive Th2 T cells are found in acute disseminated encephalomyelitis. J Neuroimmunol 1998; 91(1–2): 19–27.
Pradhan S, et al. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 1999; 165(1): 56–61.
Revel-Vilk S, et al. Recurrent acute disseminated encephalomyelitis associated with acute cytomegalovirus and Epstein–Barr virus infection. J Child Neurol 2000; 15(6): 421–4.
Richer LP, et al. Neuro-imaging features of acute disseminated encephalomyelitis in childhood. Ped Neurol 2005; 32(1): 30–6.
Rosman NP, et al. Acute hemorrhagic leukoencephalitis: Recovery and reversal of magnetic resonance imaging findings in a child. J Child Neurol 1997; 12(7): 448–54.
Rust RS. Multiple sclerosis, acute disseminated encephalomyelitis, and related conditions. Semin Pediatr Neurol 2000; 7(2): 66–90.
Sahlas DJ, et al. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology 2000; 54(6): 1370–2.
Saitoh A, et al. Acute disseminated encephalomyelitis associated with enteroviral infection. Ped Infect Dis J 2004; 23(12): 1174–5.
Schwarz S, et al. Acute disseminated encephalomyelitis: A follow-up study of 40 adult patients. Neurology 2001; 56(10): 1313–8.
Stonehouse M, et al. Acute disseminated encephalomyelitis: Recognition in the hands of general paediatricians. Arch Dis Childhood 2003; 88(2): 122–4.
Straub J, et al. Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: A successful recovery. Neurology 1997; 49(4): 1145–7.
Stuve O, Zamvil SS. Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. Curr Opin Neurol 1999; 12(4): 395–401.
Tan H, et al. Acute disseminated encephalomyelitis following hepatitis A virus infection. Ped Neurol 2004; 30(3): 207–9.
Tenembaum S, et al. Acute disseminated encephalomyelitis: A long-term follow-up study of 84 pediatric patients. Neurology 2002; 59(8): 1224–31.
Yiu E, et al. Acute transverse myelitis and acute disseminated encephalomyelitis in childhood: Spectrum or separate entities? J Child Neurol 2009; 24(3); 287–96
Zeman A, et al. The significance of serum oligoclonal bands in neurological diseases. J Neurol Neurosurg Psychiatry 1993; 56(1): 32–5.
Ziegra SR. Corticosteroid treatment for measles encephalitis. J Pediat 1961; 59: 322–3.

References

Alfonso ER, et al. Radiation myelopathy in over-irradiated patients: MR imaging findings. Eur Radiol 1997; 7: 400–40.
Alrawi A, et al. Brain biopsy in primary angiitis of the central nervous system. Neurology 1999; 53: 858–60.
Anders KH, et al. Giant cell arteritis with cerebral amyloid angiopathy: immunohistochemical and molecular studies. Hum Pathol 1997; 28: 1237–46.
Buxton N, McConachie NS. Amphetamine abuse and intracranial haemorrhage. J R Soc Med 2000; 93(9): 472–7.
Calabrese LH. Therapy of systemic vasculitis. Neurol Clin 1997; 15(4): 973–91. [Erratum appears in Neurol Clin 1998; 16(3): x.]
Calabrese LH. A headache and a mass lesion: Vasculitis or CNS sarcoid? Clin Exp Rheumatol 2003; 21(6 Suppl 32): S131–2.
Calabrese LH, Duna GF. Drug-induced vasculitis. Curr Opin Rheumatol 1996; 8(1): 34–40.
Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 1988; 67(1): 20–39.
Calabrese LH, et al. Primary angiitis of the central nervous system: Diagnostic criteria and clinical approach. Cleveland Clin J Med 1992; 59: 293–306.
Calabrese LH, et al. Benign angiopathy: A distinct subset of angiographically defined primary angiitis of the central nervous system. J Rheumatol 1993; 20(12): 2046–50.
Calabrese LH, et al. Vasculitis in the central nervous system Arthr Rheum 1997; 40(7): 1189–201.
Caselli RJ, Hunder GG. Neurologic aspects of giant cell (temporal) arteritis. Rheum Dis Clin N Am 1993; 19(4): 941–53.
Dodick DW, et al. Thunderclap headache associated with reversible vasospasm and posterior leukoencephalopathy syndrome. Cephalalgia 2003; 23(10): 994–7.
Duna GF, Calabrese LH. Limitations of invasive modalities in the diagnosis of primary angiitis of the central nervous system. J Rheumatol 1995; 22(4): 662–7.
Duna GF, Calabrese LH. Primary angiitis of the central nervous system. In Pathology and Genetics: Cerebrovascular Diseases. Basel: ISN Neuropath Press; 2005: 147–51.
Finelli PF, et al. Idiopathic granulomatous angiitis of the CNS manifesting as diffuse white matter disease. Neurology 1997; 49(6): 1696–9.
Gilden DH, et al. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342(9): 635–45.[Erratum appears in N Engl J Med 2000; 342(14): 1063.]
Gilden DH, et al. The protean manifestations of varicella-zoster virus vasculopathy. J Neurovirol 2002; 8(Suppl 2): 75–9.
Giovanini MA, et al. Granulomatous angiitis of the spinal cord: A case report. Neurosurgery 1994; 34(3): 540–3.
Gripshover BM, Ellner JJ. Chronic meningitis. In Mandell GL, et al., (Eds). Principles and Practice of Infectious Diseases. 4th edn. Philadelphia: Churchill Livingstone, 1998.
Hajj-Ali RA, et al. Benign angiopathy of the central nervous system: Cohort of 16 patients with clinical course and long-term followup. Arthr Rheum 2002; 47(6): 662–9.
Hankey GJ. Isolated angiitis/angiopathy of the central nervous system. Cerebrovasc Dis 1991; 1: 2–15.
Kadkhodayan BA, et al. Primary angiitis of the central nervous system at conventional angiography. Radiology 2004; 233(3): 878–82.
Lie JT. Malignant angioendotheliomatosis (intravascular lymphomatosis) clinically simulating primary angiitis of the central nervous system. Arthr Rheum 1992a; 35(7): 831–4.
Lie JT. Primary (granulomatous) angiitis of the central nervous system: A clinicopathologic analysis of 15 new cases and a review of the literature. Hum Pathol 1992b; 23(2): 164–71.
Moore PM. Vasculitis of the central nervous system. Semin Neurol 1994; 14(4): 307–12.
Moore PM, Calabrese LH. Neurologic manifestations of systemic vasculitides. Semin Neurol 1994; 14(4): 300–6.
Nolte KB, et al. Intracranial hemorrhage associated with cocaine abuse: A prospective autopsy study. Neurology 1996; 46(5): 1291–6.
Parisi JE, Moore PM. The role of biopsy in vasculitis of the central nervous system. Semin Neurol 1994; 14(4): 341–8.
Petty GW, et al. Cerebral ischemia in patients with hepatitis C virus infection and mixed cryoglobulinemia. Mayo Clin Proc 1996; 71(7): 671–8. [Erratum appears in Mayo Clin Proc 1996; 71(8): 824.]
Pomper MG, et al. CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. Am J Neuroradiol 1999; 20(1): 75–85.
Provenzale JM, et al. Antiphospholipid antibodies in patients without systemic lupus erythematosus: Neuroradiologic findings. Radiology 1994; 192(2): 531–7.
Rhodes RH, et al. Primary angiitis and angiopathy of the central nervous system and their relationship to systemic giant cell arteritis. Arch Pathol Lab Med 1995; 119(4): 334–49.
Ronthal M, et al. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 21–2003. A 72-year-old man with repetitive strokes in the posterior circulation N Engl J Med 2003; 349(2): 170–80.
Rosen CL, et al. Primary angiitis of the central nervous system as a first presentation in Hodgkin’s disease: A case report and review of the literature. Neurosurgery 2000; 46(6): 1504–8.
Schwab C, et al. Familial British dementia: Colocalization of furin and ABri amyloid. Acta Neuropathol 2003; 106(3): 278–84.
Singhal AB. Cerebral vasoconstriction syndromes. Top Stroke Rehab 2004; 11(2): 1–6.
Stone JH, et al. Sensitivities of noninvasive tests for central nervous system vasculitis: A comparison of lumbar puncture, computed tomography, and magnetic resonance imaging. J Rheumatol 1994; 21(7): 1277–82.
Wynne PJ, et al. Radiographic features of central nervous system vasculitis. Neurol Clin 1997; 15(4): 779–804.
Younger DS, et al. Granulomatous angiitis of the nervous system. Neurol Clin 1997; 15(4): 821–34.